Dr. Richard Lopez graduated the medical school from Stanford University School of Medicine and completed his residency program at the same university. He is specialized in Medical Oncology and also board certified in Medical Oncology. Dr. Lopez has been in practice for more than 20 years and is affiliated with University of Alabama Hospital. During his career, he has contributed to several publications of medical interest.
American Board of Internal Medicine - Oncology
LKB1 reduces ROS-mediated cell damage via activation of p38.
Xu, H. G.,Zhai, Y. X.,Chen, J.,Lu, Y.,Wang, J. W.,Quan, C. S.,Zhao, R. X.,Xiao, X.,He, Q.,Werle, K. D.,Kim, H. G.,Lopez, R.,Cui, R.,Liang, J.,Li, Y. L.,Xu, Z. X.; Oncogene. 2014 Sep 30.See more >>
Inhibiting inhibitory pathways in human γδ T cells.
Lopez, R. D.; Blood. 2013 Aug 10.See more >>
Alemtuzumab for the prevention and treatment of graft-versus-host disease.
January, C.T., Makielski, J.C., Duff, H.; Int J Hematol. 2011 May.See more >>